Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Jaguar Health, Inc.

JAGX

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Last trade $0.3401
Day change -$0.0463 (-11.98%)
Day range $0.336 – $0.402
Volume 428,643
Market cap $5M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$5.2M
Price / earnings
—
Price / book
0.79×
Price / sales
0.19×
EV / sales
0.61×
EV / EBITDA
-0.73×

Profitability

Earnings per share
-$3.93
Return on assets
-153.3%
Return on equity
-792.44%
Dividend yield
0%

Liquidity and leverage

Debt / equity
2.35×
Current ratio
0.69×
Quick ratio
0.4×
Cash ratio
0.15×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.73M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for JAGX, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$1.23M$20.27M$3.24M$3.08M$2.98M$2.21M$3.51M$3.11M
Cost of revenue$1.03M$1.16M$2.2M$532K$527K$515K$557K$541K
Gross profit$194K$19.11M$1.04M$2.55M$2.45M$1.7M$2.95M$2.57M
Selling, general and administrative$4.46M$5M$7.16M$6.13M$7.19M$7.39M$6.58M$5.79M
Research and development$3.34M$3.93M$14.31M$3.66M$3.27M$3.73M$4.53M$4.04M
Total operating expenses$7.79M$8.93M$21.48M$9.79M$10.46M$11.12M$11.11M$9.83M
Operating income-$7.6M$10.18M-$20.44M-$7.24M-$8.01M-$9.42M-$8.16M-$7.26M
Interest expense-$161K-$699K-$132K-$6K$15K$56K$110K$162K
Income before taxes-$12.8M$8.72M-$23.19M-$9.65M-$10.56M-$10.6M-$10.23M-$10.02M
Income taxes$0$0$0$0$0$0$0$0
Net income-$12.8M$8.72M-$23.19M-$9.65M-$10.56M-$10.6M-$10.23M-$10.02M
Net income attributable to common shareholders-$12.7M-$7.02M-$23.2M-$9.5M-$10.41M-$10.46M-$9.92M-$9.85M
EBITDA-$7.12M$10.66M-$19.97M-$6.76M-$7.53M-$8.94M-$7.68M-$6.79M
Basic earnings per share-$235.50-$204.00-$2,022.19-$2,997.27-$5,384.10-$8,766.75—-$12,547.50
Diluted earnings per share-$235.50-$204.00-$2,022.19-$2,997.27-$5,384.10-$8,766.75—-$12,547.50

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

Virtual Investor Conferences announced that presentations from the June 24-25 Life Sciences Virtual Investor Forum are now available for on-demand viewing for 90 days. Twenty companies across the life sciences sector presented at the forum, with select companies still accepting 1x1 management meeting requests through June 19th.

Benzinga

Why Jaguar Health Stock Is Crashing - Benzinga

Jaguar Health shares are falling after the company announced its phase 3 OnTarget trial results for crofelemer did not meet its primary endpoint. The stock has a float of only 4.889 million shares after a 1-for-60 reverse split.

Investing.com

Jaguar Health issues shares to reduce royalty debt - Investing.com

Jaguar Health, a pharmaceutical company, has issued 455,000 shares of common stock to reduce its outstanding royalty balance by $1.85 million. This move is part of the company's strategy to manage its financial liabilities and streamline its capital structure.

PennyStocks

Picking Energy Penny Stocks, 3 Tips to Use

Here's what you need to know about buying tech penny stocks in 2024 The post Picking Energy Penny Stocks, 3 Tips to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 17, 20261-for-15reverse split
Apr 30, 20261-for-35reverse split
Mar 24, 20251-for-25reverse split
May 23, 20241-for-60reverse split
Jan 23, 20231-for-75reverse split
Sep 8, 20211-for-3reverse split
Jun 7, 20191-for-70reverse split
Jun 1, 20181-for-15reverse split